| NCT ID | NCT06445361 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ziekenhuis Oost-Limburg |
| Condition | NAFLD |
| Study Type | INTERVENTIONAL |
| Enrollment | 138 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 138 participants in total. It began in 2023-07-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine the prevalence of NAFLD in T1DM patients.
Eligibility Criteria
Inclusion Criteria: * T1DM * ≥ 18 years of age * Written informed consent obtained Exclusion Criteria: * Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of liver steatosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06445361 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NAFLD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06445361 currently recruiting?
Yes, NCT06445361 is actively recruiting participants. Contact the research team at nafldstudie@zol.be for enrollment information.
Where is the NCT06445361 trial being conducted?
This trial is being conducted at Genk, Belgium.
Who is sponsoring the NCT06445361 clinical trial?
NCT06445361 is sponsored by Ziekenhuis Oost-Limburg. The trial plans to enroll 138 participants.